**************************************
Trial: NCT00931931
Conflicts: 
NCT00187031 C0079459
Intervention covered text: G-CSF
Criteria covered text: GCSF
Criterion: Growth factor(s): No PEG-GCSF within 14 days of virus injection (day 0); 
Pattern Type: ecClassifier.Rule2TimeCons

NCT00003597 C0079459
Intervention covered text: G-CSF
Criteria covered text: GCSF
Criterion: Growth factor(s): No PEG-GCSF within 14 days of virus injection (day 0); 
Pattern Type: ecClassifier.Rule2TimeCons

Total conflicts for trial NCT00931931 : 2
**************************************


**************************************
Trial: NCT01987596
Conflicts: 
NCT00187031 C0079459
Intervention covered text: G-CSF
Criteria covered text: G-CSF
Criterion: Subjects must have fully recovered from the toxic effects of any prior therapy; at least 3 weeks should have elapsed since the last dose of chemotherapy (6 weeks in the case of nitrosourea containing therapy); subjects must have recovered from previous colony-stimulating factor therapy and have been off colony-stimulating factors (G-CSF, granulocyte macrophage colony-stimulating factor [GM-CSF], interleukin [IL]-11) for more than 10 days and off erythropoietin for 30 days 
Pattern Type: ecClassifier.R14Dot8BasicOutcomeConstraint

NCT00003408 C1332791
Intervention covered text: sargramostim
Criteria covered text: granulocyte macrophage colony-stimulating factor
Criterion: Subjects must have fully recovered from the toxic effects of any prior therapy; at least 3 weeks should have elapsed since the last dose of chemotherapy (6 weeks in the case of nitrosourea containing therapy); subjects must have recovered from previous colony-stimulating factor therapy and have been off colony-stimulating factors (G-CSF, granulocyte macrophage colony-stimulating factor [GM-CSF], interleukin [IL]-11) for more than 10 days and off erythropoietin for 30 days 
Pattern Type: ecClassifier.R14Dot8BasicOutcomeConstraint

NCT00003597 C0079459
Intervention covered text: G-CSF
Criteria covered text: G-CSF
Criterion: Subjects must have fully recovered from the toxic effects of any prior therapy; at least 3 weeks should have elapsed since the last dose of chemotherapy (6 weeks in the case of nitrosourea containing therapy); subjects must have recovered from previous colony-stimulating factor therapy and have been off colony-stimulating factors (G-CSF, granulocyte macrophage colony-stimulating factor [GM-CSF], interleukin [IL]-11) for more than 10 days and off erythropoietin for 30 days 
Pattern Type: ecClassifier.R14Dot8BasicOutcomeConstraint

NCT00004157 C0537670
Intervention covered text: recombinant interleukin-11
Criteria covered text: interleukin [IL]-11
Criterion: Subjects must have fully recovered from the toxic effects of any prior therapy; at least 3 weeks should have elapsed since the last dose of chemotherapy (6 weeks in the case of nitrosourea containing therapy); subjects must have recovered from previous colony-stimulating factor therapy and have been off colony-stimulating factors (G-CSF, granulocyte macrophage colony-stimulating factor [GM-CSF], interleukin [IL]-11) for more than 10 days and off erythropoietin for 30 days 
Pattern Type: ecClassifier.R14Dot8BasicOutcomeConstraint

Total conflicts for trial NCT01987596 : 4
**************************************


**************************************
Trial: NCT01169584
Conflicts: 
Total conflicts for trial NCT01169584 : 0
**************************************


**************************************
Trial: NCT02574728
Conflicts: 
Total conflicts for trial NCT02574728 : 0
**************************************


**************************************
Trial: NCT01305200
Conflicts: 
Total conflicts for trial NCT01305200 : 0
**************************************


**************************************
Trial: NCT01625351
Conflicts: 
Total conflicts for trial NCT01625351 : 0
**************************************


**************************************
Trial: NCT00503893
Conflicts: 
Total conflicts for trial NCT00503893 : 0
**************************************


**************************************
Trial: NCT02390843
Conflicts: 
Total conflicts for trial NCT02390843 : 0
**************************************


**************************************
Trial: NCT00101270
Conflicts: 
Total conflicts for trial NCT00101270 : 0
**************************************


**************************************
Trial: NCT00187031
Conflicts: 
Total conflicts for trial NCT00187031 : 0
**************************************


**************************************
Trial: NCT00831844
Conflicts: 
Total conflicts for trial NCT00831844 : 0
**************************************


**************************************
Trial: NCT01314391
Conflicts: 
Total conflicts for trial NCT01314391 : 0
**************************************


**************************************
Trial: NCT00600119
Conflicts: 
Total conflicts for trial NCT00600119 : 0
**************************************


**************************************
Trial: NCT00152126
Conflicts: 
Total conflicts for trial NCT00152126 : 0
**************************************


**************************************
Trial: NCT01956630
Conflicts: 
Total conflicts for trial NCT01956630 : 0
**************************************


**************************************
Trial: NCT00860639
Conflicts: 
Total conflicts for trial NCT00860639 : 0
**************************************


**************************************
Trial: NCT00003887
Conflicts: 
Total conflicts for trial NCT00003887 : 0
**************************************


**************************************
Trial: NCT00897637
Conflicts: 
NCT00228696 C0205171
Intervention covered text: only
Criteria covered text: Only
Criterion: Specimens from patients previously enrolled as &quot;On Study&quot; or &quot;Followed Biology Only&quot; on protocol NWTSG-5 (COG-Q9401) 
Pattern Type: ecClassifier.R6PriorPresenceConstraint

Total conflicts for trial NCT00897637 : 1
**************************************


**************************************
Trial: NCT01445379
Conflicts: 
NCT02475707 C0205369
Intervention covered text: specific
Criteria covered text: specific
Criterion: Untreated CNS metastases will render the patient ineligible however patients with a previous history of CNS metastases are eligible if: the metastases have been treated with surgery and/or radiotherapy, are clinically stable as evidenced by no requirements for corticosteroids, the patient has no evolving neurologic deficits and no progression in residual brain abnormalities without specific therapy are eligible one week post radiation or radiosurgery.
Pattern Type: ecClassifier.R1NoPattern

NCT00436657 C0543467
Intervention covered text: Surgery
Criteria covered text: surgery
Criterion: Untreated CNS metastases will render the patient ineligible however patients with a previous history of CNS metastases are eligible if: the metastases have been treated with surgery and/or radiotherapy, are clinically stable as evidenced by no requirements for corticosteroids, the patient has no evolving neurologic deficits and no progression in residual brain abnormalities without specific therapy are eligible one week post radiation or radiosurgery.
Pattern Type: ecClassifier.R6PriorPresenceConstraint

NCT00436657 C0543467
Intervention covered text: Surgery
Criteria covered text: surgery
Criterion: Patients with asymptomatic subcentemeric CNS lesions will be eligible for trial if no immediate radiation or surgery.
Pattern Type: ecClassifier.R1NoPattern

NCT00118326 C0149615
Intervention covered text: allogeneic bone marrow transplantation
Criteria covered text: allogeneic bone marrow transplantation
Criterion: Patients with a history of allogeneic bone marrow transplantation.
Pattern Type: ecClassifier.R6PriorPresenceConstraint

NCT01576211 C1552740
Intervention covered text: specific
Criteria covered text: specific
Criterion: Untreated CNS metastases will render the patient ineligible however patients with a previous history of CNS metastases are eligible if: the metastases have been treated with surgery and/or radiotherapy, are clinically stable as evidenced by no requirements for corticosteroids, the patient has no evolving neurologic deficits and no progression in residual brain abnormalities without specific therapy are eligible one week post radiation or radiosurgery.
Pattern Type: ecClassifier.R1NoPattern

NCT00812708 C0038895
Intervention covered text: Surgery
Criteria covered text: surgery
Criterion: Untreated CNS metastases will render the patient ineligible however patients with a previous history of CNS metastases are eligible if: the metastases have been treated with surgery and/or radiotherapy, are clinically stable as evidenced by no requirements for corticosteroids, the patient has no evolving neurologic deficits and no progression in residual brain abnormalities without specific therapy are eligible one week post radiation or radiosurgery.
Pattern Type: ecClassifier.R6PriorPresenceConstraint

NCT00812708 C0038895
Intervention covered text: Surgery
Criteria covered text: surgery
Criterion: Patients with asymptomatic subcentemeric CNS lesions will be eligible for trial if no immediate radiation or surgery.
Pattern Type: ecClassifier.R1NoPattern

Total conflicts for trial NCT01445379 : 7
**************************************


**************************************
Trial: NCT01453283
Conflicts: 
NCT01987596 C1332793
Intervention covered text: filgrastim
Criteria covered text: filgrastim
Criterion: Growth factors: The last dose of growth factors such as filgrastim and epoetin must be at least one week prior to study entry, the last dose of long-acting colony stimulating factors, such as pegfilgrastim, must be 2 weeks prior to study entry.
Pattern Type: ecClassifier.R6Dot12PriorPresenceConstraintTime

NCT01305200 C1516048
Intervention covered text: assessment
Criteria covered text: assessing
Criterion: CONCOMITANT MEDICATIONS: -Patients with brain tumors must be on a stable or tapering dose of corticosteroids for 7 days prior to the date of the baseline scan performed for the purpose of assessing response to therapy on this study.
Pattern Type: ecClassifier.R68CondReq

NCT00187031 C1136535
Intervention covered text: Pegfilgrastim
Criteria covered text: pegfilgrastim
Criterion: Growth factors: The last dose of growth factors such as filgrastim and epoetin must be at least one week prior to study entry, the last dose of long-acting colony stimulating factors, such as pegfilgrastim, must be 2 weeks prior to study entry.
Pattern Type: ecClassifier.R6Dot12PriorPresenceConstraintTime

NCT00187031 C0210630
Intervention covered text: Filgrastim
Criteria covered text: filgrastim
Criterion: Growth factors: The last dose of growth factors such as filgrastim and epoetin must be at least one week prior to study entry, the last dose of long-acting colony stimulating factors, such as pegfilgrastim, must be 2 weeks prior to study entry.
Pattern Type: ecClassifier.R6Dot12PriorPresenceConstraintTime

NCT00005952 C1332793
Intervention covered text: filgrastim
Criteria covered text: filgrastim
Criterion: Growth factors: The last dose of growth factors such as filgrastim and epoetin must be at least one week prior to study entry, the last dose of long-acting colony stimulating factors, such as pegfilgrastim, must be 2 weeks prior to study entry.
Pattern Type: ecClassifier.R6Dot12PriorPresenceConstraintTime

NCT00002610 C0210630
Intervention covered text: filgrastim
Criteria covered text: filgrastim
Criterion: Growth factors: The last dose of growth factors such as filgrastim and epoetin must be at least one week prior to study entry, the last dose of long-acting colony stimulating factors, such as pegfilgrastim, must be 2 weeks prior to study entry.
Pattern Type: ecClassifier.R6Dot12PriorPresenceConstraintTime

NCT00003926 C1332793
Intervention covered text: filgrastim
Criteria covered text: filgrastim
Criterion: Growth factors: The last dose of growth factors such as filgrastim and epoetin must be at least one week prior to study entry, the last dose of long-acting colony stimulating factors, such as pegfilgrastim, must be 2 weeks prior to study entry.
Pattern Type: ecClassifier.R6Dot12PriorPresenceConstraintTime

NCT00638898 C0210630
Intervention covered text: filgrastim
Criteria covered text: filgrastim
Criterion: Growth factors: The last dose of growth factors such as filgrastim and epoetin must be at least one week prior to study entry, the last dose of long-acting colony stimulating factors, such as pegfilgrastim, must be 2 weeks prior to study entry.
Pattern Type: ecClassifier.R6Dot12PriorPresenceConstraintTime

NCT00002515 C1332793
Intervention covered text: filgrastim
Criteria covered text: filgrastim
Criterion: Growth factors: The last dose of growth factors such as filgrastim and epoetin must be at least one week prior to study entry, the last dose of long-acting colony stimulating factors, such as pegfilgrastim, must be 2 weeks prior to study entry.
Pattern Type: ecClassifier.R6Dot12PriorPresenceConstraintTime

NCT00118326 C1332793
Intervention covered text: filgrastim
Criteria covered text: filgrastim
Criterion: Growth factors: The last dose of growth factors such as filgrastim and epoetin must be at least one week prior to study entry, the last dose of long-acting colony stimulating factors, such as pegfilgrastim, must be 2 weeks prior to study entry.
Pattern Type: ecClassifier.R6Dot12PriorPresenceConstraintTime

NCT00004157 C1332793
Intervention covered text: filgrastim
Criteria covered text: filgrastim
Criterion: Growth factors: The last dose of growth factors such as filgrastim and epoetin must be at least one week prior to study entry, the last dose of long-acting colony stimulating factors, such as pegfilgrastim, must be 2 weeks prior to study entry.
Pattern Type: ecClassifier.R6Dot12PriorPresenceConstraintTime

NCT00002611 C0210630
Intervention covered text: filgrastim
Criteria covered text: filgrastim
Criterion: Growth factors: The last dose of growth factors such as filgrastim and epoetin must be at least one week prior to study entry, the last dose of long-acting colony stimulating factors, such as pegfilgrastim, must be 2 weeks prior to study entry.
Pattern Type: ecClassifier.R6Dot12PriorPresenceConstraintTime

Total conflicts for trial NCT01453283 : 12
**************************************


**************************************
Trial: NCT00003408
Conflicts: 
Total conflicts for trial NCT00003408 : 0
**************************************


**************************************
Trial: NCT01614808
Conflicts: 
Total conflicts for trial NCT01614808 : 0
**************************************


**************************************
Trial: NCT00005952
Conflicts: 
Total conflicts for trial NCT00005952 : 0
**************************************


**************************************
Trial: NCT02649582
Conflicts: 
Total conflicts for trial NCT02649582 : 0
**************************************


**************************************
Trial: NCT00088803
Conflicts: 
Total conflicts for trial NCT00088803 : 0
**************************************


**************************************
Trial: NCT02392793
Conflicts: 
Total conflicts for trial NCT02392793 : 0
**************************************


**************************************
Trial: NCT00514189
Conflicts: 
NCT00436657 C0543467
Intervention covered text: Surgery
Criteria covered text: surgical
Criterion: 7. Positive Beta HCG test in a woman with child bearing potential defined as not post-menopausal for 12 months or no previous surgical sterilization
Pattern Type: ecClassifier.Rule2PACPattern

NCT00812708 C0543467
Intervention covered text: Surgery
Criteria covered text: surgical
Criterion: 7. Positive Beta HCG test in a woman with child bearing potential defined as not post-menopausal for 12 months or no previous surgical sterilization
Pattern Type: ecClassifier.Rule2PACPattern

Total conflicts for trial NCT00514189 : 2
**************************************


**************************************
Trial: NCT00002610
Conflicts: 
Total conflicts for trial NCT00002610 : 0
**************************************


**************************************
Trial: NCT00047138
Conflicts: 
NCT00436657 C0543467
Intervention covered text: Surgery
Criteria covered text: Surgery
Criterion: No prior radiotherapy Surgery 
Pattern Type: ecClassifier.Rule2PACPattern

NCT00436657 C0543467
Intervention covered text: Surgery
Criteria covered text: surgery
Criterion: No requirement for emergency or immediate surgery for any reason 
Pattern Type: ecClassifier.R1NoPattern

NCT00812708 C0038895
Intervention covered text: Surgery
Criteria covered text: Surgery
Criterion: No prior radiotherapy Surgery 
Pattern Type: ecClassifier.Rule2PACPattern

NCT00812708 C0038895
Intervention covered text: Surgery
Criteria covered text: surgery
Criterion: No requirement for emergency or immediate surgery for any reason 
Pattern Type: ecClassifier.R1NoPattern

Total conflicts for trial NCT00047138 : 4
**************************************


**************************************
Trial: NCT00945009
Conflicts: 
Total conflicts for trial NCT00945009 : 0
**************************************


**************************************
Trial: NCT00003597
Conflicts: 
NCT02574728 C0015133
Intervention covered text: Etoposide
Criteria covered text: etoposide
Criterion: At least 3 months since therapy with etoposide, carboplatin, or ifosfamide 
Pattern Type: ecClassifier.R6Dot11PriorPresenceConstraintTime

NCT00002610 C0079083
Intervention covered text: carboplatin
Criteria covered text: carboplatin
Criterion: At least 3 months since therapy with etoposide, carboplatin, or ifosfamide 
Pattern Type: ecClassifier.R6Dot11PriorPresenceConstraintTime

NCT00002610 C0015133
Intervention covered text: etoposide
Criteria covered text: etoposide
Criterion: At least 3 months since therapy with etoposide, carboplatin, or ifosfamide 
Pattern Type: ecClassifier.R6Dot11PriorPresenceConstraintTime

NCT00047138 C0079083
Intervention covered text: carboplatin
Criteria covered text: carboplatin
Criterion: At least 3 months since therapy with etoposide, carboplatin, or ifosfamide 
Pattern Type: ecClassifier.R6Dot11PriorPresenceConstraintTime

NCT00047138 C0015133
Intervention covered text: etoposide
Criteria covered text: etoposide
Criterion: At least 3 months since therapy with etoposide, carboplatin, or ifosfamide 
Pattern Type: ecClassifier.R6Dot11PriorPresenceConstraintTime

NCT00025103 C0079083
Intervention covered text: carboplatin
Criteria covered text: carboplatin
Criterion: At least 3 months since therapy with etoposide, carboplatin, or ifosfamide 
Pattern Type: ecClassifier.R6Dot11PriorPresenceConstraintTime

NCT00025103 C0015133
Intervention covered text: etoposide
Criteria covered text: etoposide
Criterion: At least 3 months since therapy with etoposide, carboplatin, or ifosfamide 
Pattern Type: ecClassifier.R6Dot11PriorPresenceConstraintTime

NCT00002515 C0079083
Intervention covered text: carboplatin
Criteria covered text: carboplatin
Criterion: At least 3 months since therapy with etoposide, carboplatin, or ifosfamide 
Pattern Type: ecClassifier.R6Dot11PriorPresenceConstraintTime

NCT00002466 C0015133
Intervention covered text: etoposide
Criteria covered text: etoposide
Criterion: At least 3 months since therapy with etoposide, carboplatin, or ifosfamide 
Pattern Type: ecClassifier.R6Dot11PriorPresenceConstraintTime

NCT00002466 C0020823
Intervention covered text: ifosfamide
Criteria covered text: ifosfamide
Criterion: At least 3 months since therapy with etoposide, carboplatin, or ifosfamide 
Pattern Type: ecClassifier.R6Dot11PriorPresenceConstraintTime

NCT00335556 C0015133
Intervention covered text: Etoposide
Criteria covered text: etoposide
Criterion: At least 3 months since therapy with etoposide, carboplatin, or ifosfamide 
Pattern Type: ecClassifier.R6Dot11PriorPresenceConstraintTime

NCT00335556 C0079083
Intervention covered text: Carboplatin
Criteria covered text: carboplatin
Criterion: At least 3 months since therapy with etoposide, carboplatin, or ifosfamide 
Pattern Type: ecClassifier.R6Dot11PriorPresenceConstraintTime

NCT00002611 C0015133
Intervention covered text: etoposide
Criteria covered text: etoposide
Criterion: At least 3 months since therapy with etoposide, carboplatin, or ifosfamide 
Pattern Type: ecClassifier.R6Dot11PriorPresenceConstraintTime

Total conflicts for trial NCT00003597 : 13
**************************************


**************************************
Trial: NCT00038207
Conflicts: 
Total conflicts for trial NCT00038207 : 0
**************************************


**************************************
Trial: NCT01118078
Conflicts: 
Total conflicts for trial NCT01118078 : 0
**************************************


**************************************
Trial: NCT00927498
Conflicts: 
Total conflicts for trial NCT00927498 : 0
**************************************


**************************************
Trial: NCT02027805
Conflicts: 
Total conflicts for trial NCT02027805 : 0
**************************************


**************************************
Trial: NCT01236586
Conflicts: 
Total conflicts for trial NCT01236586 : 0
**************************************


**************************************
Trial: NCT01095926
Conflicts: 
Total conflicts for trial NCT01095926 : 0
**************************************


**************************************
Trial: NCT02581384
Conflicts: 
Total conflicts for trial NCT02581384 : 0
**************************************


**************************************
Trial: NCT01493817
Conflicts: 
Total conflicts for trial NCT01493817 : 0
**************************************


**************************************
Trial: NCT00036959
Conflicts: 
NCT01987596 C1332793
Intervention covered text: filgrastim
Criteria covered text: filgrastim
Criterion: At least 72 hours since prior colony-stimulating factors (e.g., filgrastim [G-CSF] or sargramostim [GM-CSF]) except epoetin alfa 
Pattern Type: ecClassifier.R6Dot11Dot1PriorPresenceConstraintTimeExcl

NCT00187031 C0210630
Intervention covered text: Filgrastim
Criteria covered text: filgrastim
Criterion: At least 72 hours since prior colony-stimulating factors (e.g., filgrastim [G-CSF] or sargramostim [GM-CSF]) except epoetin alfa 
Pattern Type: ecClassifier.R6Dot11Dot1PriorPresenceConstraintTimeExcl

NCT00187031 C0079459
Intervention covered text: G-CSF
Criteria covered text: G-CSF
Criterion: At least 72 hours since prior colony-stimulating factors (e.g., filgrastim [G-CSF] or sargramostim [GM-CSF]) except epoetin alfa 
Pattern Type: ecClassifier.R6Dot11Dot1PriorPresenceConstraintTimeExcl

NCT00003408 C0216231
Intervention covered text: sargramostim
Criteria covered text: sargramostim
Criterion: At least 72 hours since prior colony-stimulating factors (e.g., filgrastim [G-CSF] or sargramostim [GM-CSF]) except epoetin alfa 
Pattern Type: ecClassifier.R6Dot11Dot1PriorPresenceConstraintTimeExcl

NCT00005952 C1332793
Intervention covered text: filgrastim
Criteria covered text: filgrastim
Criterion: At least 72 hours since prior colony-stimulating factors (e.g., filgrastim [G-CSF] or sargramostim [GM-CSF]) except epoetin alfa 
Pattern Type: ecClassifier.R6Dot11Dot1PriorPresenceConstraintTimeExcl

NCT00002610 C0210630
Intervention covered text: filgrastim
Criteria covered text: filgrastim
Criterion: At least 72 hours since prior colony-stimulating factors (e.g., filgrastim [G-CSF] or sargramostim [GM-CSF]) except epoetin alfa 
Pattern Type: ecClassifier.R6Dot11Dot1PriorPresenceConstraintTimeExcl

NCT00003597 C0079459
Intervention covered text: G-CSF
Criteria covered text: G-CSF
Criterion: At least 72 hours since prior colony-stimulating factors (e.g., filgrastim [G-CSF] or sargramostim [GM-CSF]) except epoetin alfa 
Pattern Type: ecClassifier.R6Dot11Dot1PriorPresenceConstraintTimeExcl

NCT00003926 C1332793
Intervention covered text: filgrastim
Criteria covered text: filgrastim
Criterion: At least 72 hours since prior colony-stimulating factors (e.g., filgrastim [G-CSF] or sargramostim [GM-CSF]) except epoetin alfa 
Pattern Type: ecClassifier.R6Dot11Dot1PriorPresenceConstraintTimeExcl

NCT00638898 C0210630
Intervention covered text: filgrastim
Criteria covered text: filgrastim
Criterion: At least 72 hours since prior colony-stimulating factors (e.g., filgrastim [G-CSF] or sargramostim [GM-CSF]) except epoetin alfa 
Pattern Type: ecClassifier.R6Dot11Dot1PriorPresenceConstraintTimeExcl

NCT00002515 C1332793
Intervention covered text: filgrastim
Criteria covered text: filgrastim
Criterion: At least 72 hours since prior colony-stimulating factors (e.g., filgrastim [G-CSF] or sargramostim [GM-CSF]) except epoetin alfa 
Pattern Type: ecClassifier.R6Dot11Dot1PriorPresenceConstraintTimeExcl

NCT00118326 C1332793
Intervention covered text: filgrastim
Criteria covered text: filgrastim
Criterion: At least 72 hours since prior colony-stimulating factors (e.g., filgrastim [G-CSF] or sargramostim [GM-CSF]) except epoetin alfa 
Pattern Type: ecClassifier.R6Dot11Dot1PriorPresenceConstraintTimeExcl

NCT00004157 C0537670
Intervention covered text: recombinant interleukin-11
Criteria covered text: interleukin-11
Criterion: At least 72 hours since prior interleukin-11 
Pattern Type: ecClassifier.R6Dot11PriorPresenceConstraintTime

NCT00004157 C1332793
Intervention covered text: filgrastim
Criteria covered text: filgrastim
Criterion: At least 72 hours since prior colony-stimulating factors (e.g., filgrastim [G-CSF] or sargramostim [GM-CSF]) except epoetin alfa 
Pattern Type: ecClassifier.R6Dot11Dot1PriorPresenceConstraintTimeExcl

NCT00004157 C0537670
Intervention covered text: recombinant interleukin-11
Criteria covered text: interleukin-11
Criterion: No concurrent interleukin-11 
Pattern Type: ecClassifier.R1NoPattern

NCT00002611 C0210630
Intervention covered text: filgrastim
Criteria covered text: filgrastim
Criterion: At least 72 hours since prior colony-stimulating factors (e.g., filgrastim [G-CSF] or sargramostim [GM-CSF]) except epoetin alfa 
Pattern Type: ecClassifier.R6Dot11Dot1PriorPresenceConstraintTimeExcl

Total conflicts for trial NCT00036959 : 15
**************************************


**************************************
Trial: NCT00674193
Conflicts: 
Total conflicts for trial NCT00674193 : 0
**************************************


**************************************
Trial: NCT00352534
Conflicts: 
Total conflicts for trial NCT00352534 : 0
**************************************


**************************************
Trial: NCT01035307
Conflicts: 
Total conflicts for trial NCT01035307 : 0
**************************************


**************************************
Trial: NCT00066599
Conflicts: 
NCT02574728 C0072980
Intervention covered text: Sirolimus
Criteria covered text: sirolimus
Criterion: No prior sirolimus 
Pattern Type: ecClassifier.Rule2PACPattern

NCT01625351 C0072980
Intervention covered text: sirolimus
Criteria covered text: sirolimus
Criterion: No prior sirolimus 
Pattern Type: ecClassifier.Rule2PACPattern

NCT01331135 C0072980
Intervention covered text: sirolimus
Criteria covered text: sirolimus
Criterion: No prior sirolimus 
Pattern Type: ecClassifier.Rule2PACPattern

Total conflicts for trial NCT00066599 : 3
**************************************


**************************************
Trial: NCT00369564
Conflicts: 
Total conflicts for trial NCT00369564 : 0
**************************************


**************************************
Trial: NCT01048892
Conflicts: 
Total conflicts for trial NCT01048892 : 0
**************************************


**************************************
Trial: NCT00228696
Conflicts: 
Total conflicts for trial NCT00228696 : 0
**************************************


**************************************
Trial: NCT02472691
Conflicts: 
Total conflicts for trial NCT02472691 : 0
**************************************


**************************************
Trial: NCT01706185
Conflicts: 
NCT01305200 C1261322
Intervention covered text: assessment
Criteria covered text: investigation
Criterion: Many patients may no longer be alive, or no longer be in contact with the investigation sites.
Pattern Type: ecClassifier.R1NoPattern

NCT00436657 C0543467
Intervention covered text: Surgery
Criteria covered text: operative technique
Criterion: There are no restrictions regarding operative technique (cystectomy or cystoscopy).
Pattern Type: ecClassifier.R1NoPattern

NCT00812708 C0038895
Intervention covered text: Surgery
Criteria covered text: operative technique
Criterion: There are no restrictions regarding operative technique (cystectomy or cystoscopy).
Pattern Type: ecClassifier.R1NoPattern

Total conflicts for trial NCT01706185 : 3
**************************************


**************************************
Trial: NCT00898755
Conflicts: 
Total conflicts for trial NCT00898755 : 0
**************************************


**************************************
Trial: NCT01542333
Conflicts: 
Total conflicts for trial NCT01542333 : 0
**************************************


**************************************
Trial: NCT02164097
Conflicts: 
Total conflicts for trial NCT02164097 : 0
**************************************


**************************************
Trial: NCT01130623
Conflicts: 
Total conflicts for trial NCT01130623 : 0
**************************************


**************************************
Trial: NCT02425397
Conflicts: 
Total conflicts for trial NCT02425397 : 0
**************************************


**************************************
Trial: NCT00379340
Conflicts: 
Total conflicts for trial NCT00379340 : 0
**************************************


**************************************
Trial: NCT02203903
Conflicts: 
Total conflicts for trial NCT02203903 : 0
**************************************


**************************************
Trial: NCT00303940
Conflicts: 
Total conflicts for trial NCT00303940 : 0
**************************************


**************************************
Trial: NCT00405327
Conflicts: 
NCT01625351 C0038250
Intervention covered text: stem cells
Criteria covered text: stem cells
Criterion: Patients who also have previously had tumor or stem cells collected, which are available and sufficient for this study, are eligible to participate as study subjects.
Pattern Type: ecClassifier.R6PriorPresenceConstraint

NCT00005952 C0242602
Intervention covered text: peripheral blood stem cell transplantation
Criteria covered text: peripheral blood stem cell transplantation
Criterion: 8. Patients may have undergone prior autologous peripheral blood stem cell transplantation, provided at least 12 months have elapsed prior to entry on this study.
Pattern Type: ecClassifier.R6Dot12PriorPresenceConstraintTime

NCT00228696 C0205171
Intervention covered text: only
Criteria covered text: only
Criterion: Because patients may enter this study prior to completion of retransplant treatments, the below criteria must be met only to proceed to the high dose chemotherapy and autologous stem cell transplant part of this study.
Pattern Type: ecClassifier.R6PriorPresenceConstraint

NCT00003926 C0242602
Intervention covered text: peripheral blood stem cell transplantation
Criteria covered text: peripheral blood stem cell transplantation
Criterion: 8. Patients may have undergone prior autologous peripheral blood stem cell transplantation, provided at least 12 months have elapsed prior to entry on this study.
Pattern Type: ecClassifier.R6Dot12PriorPresenceConstraintTime

NCT00003926 C1518999
Intervention covered text: PBSC
Criteria covered text: PBSCs
Criterion: 9. Patients must have had a successful peripheral blood stem cell collection, with cryopreservation of PBSCs for both engraftment and for generation of dendritic cells.
Pattern Type: ecClassifier.R6Dot3PriorPresenceConstraintTherapy

NCT00179816 C1328050
Intervention covered text: High-Dose Chemotherapy
Criteria covered text: high dose chemotherapy
Criterion: Because patients may enter this study prior to completion of retransplant treatments, the below criteria must be met only to proceed to the high dose chemotherapy and autologous stem cell transplant part of this study.
Pattern Type: ecClassifier.R6PriorPresenceConstraint

NCT00179816 C1518999
Intervention covered text: PBSC
Criteria covered text: PBSCs
Criterion: 9. Patients must have had a successful peripheral blood stem cell collection, with cryopreservation of PBSCs for both engraftment and for generation of dendritic cells.
Pattern Type: ecClassifier.R6Dot3PriorPresenceConstraintTherapy

NCT00025103 C0242602
Intervention covered text: peripheral blood stem cell transplantation
Criteria covered text: peripheral blood stem cell transplantation
Criterion: 8. Patients may have undergone prior autologous peripheral blood stem cell transplantation, provided at least 12 months have elapsed prior to entry on this study.
Pattern Type: ecClassifier.R6Dot12PriorPresenceConstraintTime

Total conflicts for trial NCT00405327 : 8
**************************************


**************************************
Trial: NCT00003926
Conflicts: 
Total conflicts for trial NCT00003926 : 0
**************************************


**************************************
Trial: NCT00179816
Conflicts: 
Total conflicts for trial NCT00179816 : 0
**************************************


**************************************
Trial: NCT02018458
Conflicts: 
Total conflicts for trial NCT02018458 : 0
**************************************


**************************************
Trial: NCT00020150
Conflicts: 
NCT01987596 C1332793
Intervention covered text: filgrastim
Criteria covered text: filgrastim
Criterion: At least 1 week since prior colony-stimulating factors (e.g., filgrastim [G- CSF], sargramostim [GM-CSF], or epoetin alfa) 
Pattern Type: ecClassifier.R6Dot11PriorPresenceConstraintTime

NCT00187031 C0210630
Intervention covered text: Filgrastim
Criteria covered text: filgrastim
Criterion: At least 1 week since prior colony-stimulating factors (e.g., filgrastim [G- CSF], sargramostim [GM-CSF], or epoetin alfa) 
Pattern Type: ecClassifier.R6Dot11PriorPresenceConstraintTime

NCT00187031 C0079459
Intervention covered text: G-CSF
Criteria covered text: G- CSF
Criterion: At least 1 week since prior colony-stimulating factors (e.g., filgrastim [G- CSF], sargramostim [GM-CSF], or epoetin alfa) 
Pattern Type: ecClassifier.R6Dot11PriorPresenceConstraintTime

NCT00003408 C0216231
Intervention covered text: sargramostim
Criteria covered text: sargramostim
Criterion: At least 1 week since prior colony-stimulating factors (e.g., filgrastim [G- CSF], sargramostim [GM-CSF], or epoetin alfa) 
Pattern Type: ecClassifier.R6Dot11PriorPresenceConstraintTime

NCT00005952 C0076080
Intervention covered text: temozolomide
Criteria covered text: temozolomide
Criterion: No prior hypersensitivity to dacarbazine, temozolomide, or polyethylene glycol 
Pattern Type: ecClassifier.R14Dot6BasicAdverseReacContra

NCT00005952 C1332793
Intervention covered text: filgrastim
Criteria covered text: filgrastim
Criterion: At least 1 week since prior colony-stimulating factors (e.g., filgrastim [G- CSF], sargramostim [GM-CSF], or epoetin alfa) 
Pattern Type: ecClassifier.R6Dot11PriorPresenceConstraintTime

NCT00005952 C0076080
Intervention covered text: temozolomide
Criteria covered text: temozolomide
Criterion: Prior temozolomide allowed provided not administered within past 3 months, no severe toxicities experienced during prior course, and not given in combination with other agents designed to inactivate alanine-glyoxylate aminotransferase 
Pattern Type: ecClassifier.R6Dot9PriorPresenceConstraintTime

NCT00002610 C0210630
Intervention covered text: filgrastim
Criteria covered text: filgrastim
Criterion: At least 1 week since prior colony-stimulating factors (e.g., filgrastim [G- CSF], sargramostim [GM-CSF], or epoetin alfa) 
Pattern Type: ecClassifier.R6Dot11PriorPresenceConstraintTime

NCT00003597 C0079459
Intervention covered text: G-CSF
Criteria covered text: G- CSF
Criterion: At least 1 week since prior colony-stimulating factors (e.g., filgrastim [G- CSF], sargramostim [GM-CSF], or epoetin alfa) 
Pattern Type: ecClassifier.R6Dot11PriorPresenceConstraintTime

NCT00003926 C1332793
Intervention covered text: filgrastim
Criteria covered text: filgrastim
Criterion: At least 1 week since prior colony-stimulating factors (e.g., filgrastim [G- CSF], sargramostim [GM-CSF], or epoetin alfa) 
Pattern Type: ecClassifier.R6Dot11PriorPresenceConstraintTime

NCT00638898 C0210630
Intervention covered text: filgrastim
Criteria covered text: filgrastim
Criterion: At least 1 week since prior colony-stimulating factors (e.g., filgrastim [G- CSF], sargramostim [GM-CSF], or epoetin alfa) 
Pattern Type: ecClassifier.R6Dot11PriorPresenceConstraintTime

NCT00002515 C1332793
Intervention covered text: filgrastim
Criteria covered text: filgrastim
Criterion: At least 1 week since prior colony-stimulating factors (e.g., filgrastim [G- CSF], sargramostim [GM-CSF], or epoetin alfa) 
Pattern Type: ecClassifier.R6Dot11PriorPresenceConstraintTime

NCT00118326 C1332793
Intervention covered text: filgrastim
Criteria covered text: filgrastim
Criterion: At least 1 week since prior colony-stimulating factors (e.g., filgrastim [G- CSF], sargramostim [GM-CSF], or epoetin alfa) 
Pattern Type: ecClassifier.R6Dot11PriorPresenceConstraintTime

NCT00004157 C1332793
Intervention covered text: filgrastim
Criteria covered text: filgrastim
Criterion: At least 1 week since prior colony-stimulating factors (e.g., filgrastim [G- CSF], sargramostim [GM-CSF], or epoetin alfa) 
Pattern Type: ecClassifier.R6Dot11PriorPresenceConstraintTime

NCT00002611 C0210630
Intervention covered text: filgrastim
Criteria covered text: filgrastim
Criterion: At least 1 week since prior colony-stimulating factors (e.g., filgrastim [G- CSF], sargramostim [GM-CSF], or epoetin alfa) 
Pattern Type: ecClassifier.R6Dot11PriorPresenceConstraintTime

Total conflicts for trial NCT00020150 : 15
**************************************


**************************************
Trial: NCT00025103
Conflicts: 
Total conflicts for trial NCT00025103 : 0
**************************************


**************************************
Trial: NCT02624388
Conflicts: 
Total conflicts for trial NCT02624388 : 0
**************************************


**************************************
Trial: NCT01353300
Conflicts: 
Total conflicts for trial NCT01353300 : 0
**************************************


**************************************
Trial: NCT00349024
Conflicts: 
Total conflicts for trial NCT00349024 : 0
**************************************


**************************************
Trial: NCT02543749
Conflicts: 
Total conflicts for trial NCT02543749 : 0
**************************************


**************************************
Trial: NCT00030108
Conflicts: 
Total conflicts for trial NCT00030108 : 0
**************************************


**************************************
Trial: NCT02461121
Conflicts: 
Total conflicts for trial NCT02461121 : 0
**************************************


**************************************
Trial: NCT00361296
Conflicts: 
Total conflicts for trial NCT00361296 : 0
**************************************


**************************************
Trial: NCT00019630
Conflicts: 
NCT00405327 C0027651
Intervention covered text: Tumor
Criteria covered text: tumor
Criterion: Concurrent corticosteroids for brain tumor-associated edema allowed (must be on stable or decreasing dose for at least 1 week prior to study) 
Pattern Type: ecClassifier.R6Dot12PriorPresenceConstraintTime

Total conflicts for trial NCT00019630 : 1
**************************************


**************************************
Trial: NCT00011414
Conflicts: 
Total conflicts for trial NCT00011414 : 0
**************************************


**************************************
Trial: NCT01550393
Conflicts: 
Total conflicts for trial NCT01550393 : 0
**************************************


**************************************
Trial: NCT02647359
Conflicts: 
Total conflicts for trial NCT02647359 : 0
**************************************


**************************************
Trial: NCT00638898
Conflicts: 
NCT01305200 C1261322
Intervention covered text: assessment
Criteria covered text: evaluation
Criterion: Histologically confirmed bone marrow metastases within 30 days prior to transplant; prior bone marrow metastases with clearing of bone marrow (&lt; 5% contamination as measured by bilateral bone marrow biopsies) at the time for evaluation for this protocol is acceptable 
Pattern Type: ecClassifier.R14Dot2BasicConfConstraint

NCT01625351 C0038250
Intervention covered text: stem cells
Criteria covered text: stem cell
Criterion: No contraindications to the stem cell collection by apheresis or by bone marrow harvesting
Pattern Type: ecClassifier.R1NoPattern

Total conflicts for trial NCT00638898 : 2
**************************************


**************************************
Trial: NCT02595255
Conflicts: 
NCT00436657 C0543467
Intervention covered text: Surgery
Criteria covered text: surgery
Criterion: Current or previous ovarian disease/surgery 
Pattern Type: ecClassifier.R6PriorPresenceConstraint

NCT00436657 C0543467
Intervention covered text: Surgery
Criteria covered text: surgical
Criterion: Familial history of premature ovarian failure (no iatrogenic or surgical origins) 
Pattern Type: ecClassifier.R1NoPattern

NCT00812708 C0038895
Intervention covered text: Surgery
Criteria covered text: surgery
Criterion: Current or previous ovarian disease/surgery 
Pattern Type: ecClassifier.R6PriorPresenceConstraint

NCT00812708 C0543467
Intervention covered text: Surgery
Criteria covered text: surgical
Criterion: Familial history of premature ovarian failure (no iatrogenic or surgical origins) 
Pattern Type: ecClassifier.R1NoPattern

Total conflicts for trial NCT02595255 : 4
**************************************


**************************************
Trial: NCT00002515
Conflicts: 
Total conflicts for trial NCT00002515 : 0
**************************************


**************************************
Trial: NCT02494167
Conflicts: 
Total conflicts for trial NCT02494167 : 0
**************************************


**************************************
Trial: NCT01502410
Conflicts: 
Total conflicts for trial NCT01502410 : 0
**************************************


**************************************
Trial: NCT01222780
Conflicts: 
NCT00002610 C0042680
Intervention covered text: vincristine sulfate
Criteria covered text: vincristine sulfate
Criterion: History of allergic reactions or serious adverse events attributed to compounds of similar chemical or biologic composition to vincristine or components of Marqibo(Registered Trademark) (vincristine sulfate injection, sphingomyelin/cholesterol liposomes, sodium phosphate injection).
Pattern Type: ecClassifier.R6PriorPresenceConstraint

NCT00047138 C0042680
Intervention covered text: vincristine sulfate
Criteria covered text: vincristine sulfate
Criterion: History of allergic reactions or serious adverse events attributed to compounds of similar chemical or biologic composition to vincristine or components of Marqibo(Registered Trademark) (vincristine sulfate injection, sphingomyelin/cholesterol liposomes, sodium phosphate injection).
Pattern Type: ecClassifier.R6PriorPresenceConstraint

NCT00025103 C0042680
Intervention covered text: vincristine sulfate
Criteria covered text: vincristine sulfate
Criterion: History of allergic reactions or serious adverse events attributed to compounds of similar chemical or biologic composition to vincristine or components of Marqibo(Registered Trademark) (vincristine sulfate injection, sphingomyelin/cholesterol liposomes, sodium phosphate injection).
Pattern Type: ecClassifier.R6PriorPresenceConstraint

NCT00002466 C0042680
Intervention covered text: vincristine sulfate
Criteria covered text: vincristine sulfate
Criterion: History of allergic reactions or serious adverse events attributed to compounds of similar chemical or biologic composition to vincristine or components of Marqibo(Registered Trademark) (vincristine sulfate injection, sphingomyelin/cholesterol liposomes, sodium phosphate injection).
Pattern Type: ecClassifier.R6PriorPresenceConstraint

NCT00003804 C0042680
Intervention covered text: vincristine sulfate
Criteria covered text: vincristine sulfate
Criterion: History of allergic reactions or serious adverse events attributed to compounds of similar chemical or biologic composition to vincristine or components of Marqibo(Registered Trademark) (vincristine sulfate injection, sphingomyelin/cholesterol liposomes, sodium phosphate injection).
Pattern Type: ecClassifier.R6PriorPresenceConstraint

NCT00335556 C0042680
Intervention covered text: Vincristine Sulfate
Criteria covered text: vincristine sulfate
Criterion: History of allergic reactions or serious adverse events attributed to compounds of similar chemical or biologic composition to vincristine or components of Marqibo(Registered Trademark) (vincristine sulfate injection, sphingomyelin/cholesterol liposomes, sodium phosphate injection).
Pattern Type: ecClassifier.R6PriorPresenceConstraint

NCT00002611 C0042680
Intervention covered text: vincristine sulfate
Criteria covered text: vincristine sulfate
Criterion: History of allergic reactions or serious adverse events attributed to compounds of similar chemical or biologic composition to vincristine or components of Marqibo(Registered Trademark) (vincristine sulfate injection, sphingomyelin/cholesterol liposomes, sodium phosphate injection).
Pattern Type: ecClassifier.R6PriorPresenceConstraint

Total conflicts for trial NCT01222780 : 7
**************************************


**************************************
Trial: NCT01004783
Conflicts: 
Total conflicts for trial NCT01004783 : 0
**************************************


**************************************
Trial: NCT02475707
Conflicts: 
NCT01625351 C0038250
Intervention covered text: stem cells
Criteria covered text: stem cell
Criterion: If a donor has been chosen for the transplant based on urgent medical need, that same donor will also be used for T cell generation, provided that there are no new reasons for ineligibility since the stem cell collection.
Pattern Type: ecClassifier.R1NoPattern

NCT01956630 C1512034
Intervention covered text: Donor leukocyte infusions
Criteria covered text: Donor Lymphocyte Infusion
Criterion: 2. Patients receiving a Donor Lymphocyte Infusion (DLI) within 4 weeks of planned T cell infusion.
Pattern Type: ecClassifier.R6Dot9PriorPresenceConstraintTime

Total conflicts for trial NCT02475707 : 2
**************************************


**************************************
Trial: NCT00909168
Conflicts: 
Total conflicts for trial NCT00909168 : 0
**************************************


**************************************
Trial: NCT01576198
Conflicts: 
Total conflicts for trial NCT01576198 : 0
**************************************


**************************************
Trial: NCT00623077
Conflicts: 
Total conflicts for trial NCT00623077 : 0
**************************************


**************************************
Trial: NCT00433745
Conflicts: 
Total conflicts for trial NCT00433745 : 0
**************************************


**************************************
Trial: NCT00020579
Conflicts: 
Total conflicts for trial NCT00020579 : 0
**************************************


**************************************
Trial: NCT00331643
Conflicts: 
Total conflicts for trial NCT00331643 : 0
**************************************


**************************************
Trial: NCT00003103
Conflicts: 
Total conflicts for trial NCT00003103 : 0
**************************************


**************************************
Trial: NCT00898365
Conflicts: 
NCT00436657 C0543467
Intervention covered text: Surgery
Criteria covered text: surgical
Criterion: For patients with clinical features and required imaging findings consistent with the eligibility for the bilateral study, AREN0534 (or successor study), confirmed by central review, biopsy is not required; however, if biopsy is done, tissue must be submitted as for other renal tumors, and initial risk assignment will require pathology and surgical rapid central reviews; transmittal form and pathology checklist are also needed 
Pattern Type: ecClassifier.R14Dot3BasicConfConstraint

NCT00812708 C0543467
Intervention covered text: Surgery
Criteria covered text: surgical
Criterion: For patients with clinical features and required imaging findings consistent with the eligibility for the bilateral study, AREN0534 (or successor study), confirmed by central review, biopsy is not required; however, if biopsy is done, tissue must be submitted as for other renal tumors, and initial risk assignment will require pathology and surgical rapid central reviews; transmittal form and pathology checklist are also needed 
Pattern Type: ecClassifier.R14Dot3BasicConfConstraint

Total conflicts for trial NCT00898365 : 2
**************************************


**************************************
Trial: NCT01642095
Conflicts: 
Total conflicts for trial NCT01642095 : 0
**************************************


**************************************
Trial: NCT00024258
Conflicts: 
Total conflicts for trial NCT00024258 : 0
**************************************


**************************************
Trial: NCT01132911
Conflicts: 
NCT02475707 C0205369
Intervention covered text: specific
Criteria covered text: specified
Criterion: Must have fully recovered from acute toxic effects from all prior therapy which have been completed within the specified prior time frame.
Pattern Type: ecClassifier.R6PriorPresenceConstraint

NCT01576211 C0205369
Intervention covered text: specific
Criteria covered text: specified
Criterion: Must have fully recovered from acute toxic effects from all prior therapy which have been completed within the specified prior time frame.
Pattern Type: ecClassifier.R6PriorPresenceConstraint

Total conflicts for trial NCT01132911 : 2
**************************************


**************************************
Trial: NCT00624962
Conflicts: 
NCT00405327 C0472699
Intervention covered text: Hematopoietic stem cell transplantation
Criteria covered text: hematopoietic stem cell transplant
Criterion: No prior hematopoietic stem cell transplant 
Pattern Type: ecClassifier.Rule2PACPattern

Total conflicts for trial NCT00624962 : 1
**************************************


**************************************
Trial: NCT00788125
Conflicts: 
Total conflicts for trial NCT00788125 : 0
**************************************


**************************************
Trial: NCT01331135
Conflicts: 
Total conflicts for trial NCT01331135 : 0
**************************************


**************************************
Trial: NCT01661400
Conflicts: 
Total conflicts for trial NCT01661400 : 0
**************************************


**************************************
Trial: NCT00436657
Conflicts: 
NCT00405327 C0027651
Intervention covered text: Tumor
Criteria covered text: tumor
Criterion: 5. Radiologic workup or prior abdominal exploration must be consistent with disease which can be debulked to a residual size of less than or equal to 1 mm thickness per tumor deposit
Pattern Type: ecClassifier.R6PriorPresenceConstraint

NCT00405327 C0027651
Intervention covered text: Tumor
Criteria covered text: tumors
Criterion: 2. Patients with tumors that are unable to be controlled outside the abdominal cavity will be ineligible
Pattern Type: ecClassifier.R70ExpExcl

NCT01277744 C0031153
Intervention covered text: Peritoneal
Criteria covered text: peritoneal
Criterion: 2. Histologically proven diffuse peritoneal or retroperitoneal tumor from the following histologies: adenocarcinoma of the gastrointestinal tract, desmoplastic round cell tumor, late stage neuroblastoma, ovarian germ cell, sarcoma, adrenocorticocarcinoma, Wilms', rhabdomyosarcoma.
Pattern Type: ecClassifier.R14Dot4Dot2BasicConfConstraintSpecific

NCT01277744 C1512558
Intervention covered text: Hyperthermic Peritoneal Perfusion
Criteria covered text: hyperthermic intraperitoneal perfusion
Criterion: 1. Patients who have failed previous continuous hyperthermic intraperitoneal perfusion with platinum therapy will be ineligible
Pattern Type: ecClassifier.R6PriorPresenceConstraint

Total conflicts for trial NCT00436657 : 4
**************************************


**************************************
Trial: NCT00002466
Conflicts: 
Total conflicts for trial NCT00002466 : 0
**************************************


**************************************
Trial: NCT00336531
Conflicts: 
NCT00179816 C1328050
Intervention covered text: High-Dose Chemotherapy
Criteria covered text: high dose chemotherapy
Criterion: Significant organ toxicity (National Cancer Institute [NCI] grade &gt; 2) prior to high dose chemotherapy and autologous hematopoietic stem cell transplantation 
Pattern Type: ecClassifier.R6Dot12PriorPresenceConstraintTime

NCT00638898 C1831743
Intervention covered text: autologous hematopoietic stem cell transplantation
Criteria covered text: autologous hematopoietic stem cell transplantation
Criterion: Significant organ toxicity (National Cancer Institute [NCI] grade &gt; 2) prior to high dose chemotherapy and autologous hematopoietic stem cell transplantation 
Pattern Type: ecClassifier.R6Dot12PriorPresenceConstraintTime

Total conflicts for trial NCT00336531 : 2
**************************************


**************************************
Trial: NCT00118326
Conflicts: 
Total conflicts for trial NCT00118326 : 0
**************************************


**************************************
Trial: NCT00365768
Conflicts: 
Total conflicts for trial NCT00365768 : 0
**************************************


**************************************
Trial: NCT00309907
Conflicts: 
Total conflicts for trial NCT00309907 : 0
**************************************


**************************************
Trial: NCT01576211
Conflicts: 
Total conflicts for trial NCT01576211 : 0
**************************************


**************************************
Trial: NCT01808079
Conflicts: 
Total conflicts for trial NCT01808079 : 0
**************************************


**************************************
Trial: NCT02428543
Conflicts: 
Total conflicts for trial NCT02428543 : 0
**************************************


**************************************
Trial: NCT00001509
Conflicts: 
Total conflicts for trial NCT00001509 : 0
**************************************


**************************************
Trial: NCT02162732
Conflicts: 
Total conflicts for trial NCT02162732 : 0
**************************************


**************************************
Trial: NCT01154816
Conflicts: 
Total conflicts for trial NCT01154816 : 0
**************************************


**************************************
Trial: NCT02452554
Conflicts: 
NCT00187031 C1136535
Intervention covered text: Pegfilgrastim
Criteria covered text: pegfilgrastim
Criterion: Hematopoietic growth factors: at least 14 days must have elapsed after receiving pegfilgrastim and least 7 days must have elapsed since the completion of therapy with a non-pegylated growth factor 
Pattern Type: ecClassifier.R6Dot11PriorPresenceConstraintTime

NCT00436657 C0543467
Intervention covered text: Surgery
Criteria covered text: surgically
Criterion: Patients must not have known active central nervous system (CNS) metastases; patients with known central nervous system metastases are excluded unless treated surgically or with radiotherapy, and stable with no recurrent lesions for at least 6 months 
Pattern Type: ecClassifier.R1NoPattern

NCT00812708 C0543467
Intervention covered text: Surgery
Criteria covered text: surgically
Criterion: Patients must not have known active central nervous system (CNS) metastases; patients with known central nervous system metastases are excluded unless treated surgically or with radiotherapy, and stable with no recurrent lesions for at least 6 months 
Pattern Type: ecClassifier.R1NoPattern

Total conflicts for trial NCT02452554 : 3
**************************************


**************************************
Trial: NCT00012181
Conflicts: 
NCT01236586 C0011777
Intervention covered text: Dexamethasone
Criteria covered text: dexamethasone
Criterion: Concurrent dexamethasone for CNS tumors allowed if on stable dose for at least 2 weeks prior to study 
Pattern Type: ecClassifier.R6Dot12PriorPresenceConstraintTime

Total conflicts for trial NCT00012181 : 1
**************************************


**************************************
Trial: NCT01586104
Conflicts: 
Total conflicts for trial NCT01586104 : 0
**************************************


**************************************
Trial: NCT00812708
Conflicts: 
Total conflicts for trial NCT00812708 : 0
**************************************


**************************************
Trial: NCT01277744
Conflicts: 
NCT00405327 C0027651
Intervention covered text: Tumor
Criteria covered text: tumors
Criterion: 2. Histologically or genetically proven diffuse peritoneal or retroperitoneal tumor from desmoplastic round cell tumor, ovarian germ cell, sarcoma, Wilms' tumor, or other non-carcinoma tumors.
Pattern Type: ecClassifier.R14Dot4Dot2BasicConfConstraintSpecific

NCT00405327 C0027651
Intervention covered text: Tumor
Criteria covered text: tumor
Criterion: 4. Radiologic workup or prior abdominal exploration must be consistent with disease which can be debulked to a residual size of less than or equal to 1 cm thickness per tumor deposit
Pattern Type: ecClassifier.R6PriorPresenceConstraint

Total conflicts for trial NCT01277744 : 2
**************************************


**************************************
Trial: NCT01598454
Conflicts: 
Total conflicts for trial NCT01598454 : 0
**************************************


**************************************
Trial: NCT00036712
Conflicts: 
Total conflicts for trial NCT00036712 : 0
**************************************


**************************************
Trial: NCT00003804
Conflicts: 
Total conflicts for trial NCT00003804 : 0
**************************************


**************************************
Trial: NCT00004157
Conflicts: 
Total conflicts for trial NCT00004157 : 0
**************************************


**************************************
Trial: NCT01860612
Conflicts: 
Total conflicts for trial NCT01860612 : 0
**************************************


**************************************
Trial: NCT00335556
Conflicts: 
Total conflicts for trial NCT00335556 : 0
**************************************


**************************************
Trial: NCT00002611
Conflicts: 
Total conflicts for trial NCT00002611 : 0
**************************************


**************************************
Trial: NCT00728585
Conflicts: 
Total conflicts for trial NCT00728585 : 0
**************************************


**************************************
Trial: NCT01132547
Conflicts: 
Total conflicts for trial NCT01132547 : 0
**************************************


**************************************
Trial: NCT00003107
Conflicts: 
Total conflicts for trial NCT00003107 : 0
**************************************


**************************************
Trial: NCT00141765
Conflicts: 
Total conflicts for trial NCT00141765 : 0
**************************************


